BioCentury
ARTICLE | Clinical News

NGD 97-1: Began Phase I testing

February 8, 1999 8:00 AM UTC

Neurogen Corp. (NRGN), Branford, Conn. Product: NGD 97-1 Business: Neurological Therapeutic category: Neurotransmission Target: GABA receptors Description: Small molecule GABA receptor modulator Indi...